The microbiome and diverticulitis: A new target for medical therapy?

Diseases of the Colon and Rectum

Volumn 57, Issue 4, 2014, Pages 544-545

  Hall, Jason F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; MESALAZINE; RIFAXIMIN; SULTAMICILLIN;

COLON CANCER; DEFECATION HABIT; DIVERTICULITIS; DIVERTICULOSIS; GASTROINTESTINAL TRACT FUNCTION; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; MICROBIOME; MICROFLORA; OBESITY; PATHOGENESIS; PATIENT; REVIEW;

DIVERTICULOSIS, COLONIC; HUMANS; INTESTINAL MUCOSA; MICROBIOTA;

EID: 84898745368     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0000000000000077     Document Type: Review

References (15)

1. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312:1355-1359.
2. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-415.
3. Stumpf RA, Wilson BA, Rivera A, et al. The primate vaginal microbiome: comparative context and implications for human health and disease. Am J Phys Anthropol. 2013;152(suppl 57):119-134.
4. Hall J, Hammerich K, Roberts P. New paradigms in the management of diverticular disease. Curr Probl Surg. 2010;47:680-735.
5. Mulhall AM, Mahid SS, Petras RE, Galandiuk S. Diverticular disease associated with inflammatory bowel disease-like colitis: a systematic review. Dis Colon Rectum. 2009;52:1072-1079.
6. Peppercorn MA. The overlap of inflammatory bowel disease and diverticular disease. J Clin Gastroenterol. 2004;38(5 suppl 1):S8-S10.
7. Horgan AF, McConnell EJ, Wolff BG, The S, Paterson C. Atypical diverticular disease: surgical results. Dis Colon Rectum. 2001;44:1315-1318.
8. Floch MH. A hypothesis: is diverticulitis a type of inflammatory bowel disease? J Clin Gastroenterol. 2006;40(suppl 3):S121-S125.
9. Trepsi E, Colla C, Panizza P, et al. Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results [in Italian]. Minerva Gastroenterol Dietol. 1999;45:245-252.
10. Strate LL. Lifestyle factors and the course of diverticular disease. Dig Dis. 2012;30:35-45.
11. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004;101:15718-15723.
12. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913-6.e7.
13. Trespi E, Colla C, Panizza P, et al. Ruolo terapeutio e profilattico della mesalazina nella malattia diverticulare sintomatica del crasso. Minerva Gastroenterol Dietol. 1999;45:245-252.
14. Tursi A, Brandimarte G, Daffinà R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis. 2002;34:510-515.
15. Gatta L, Vakil N, Vaira D, et al. Efficacy of 5-ASA in the treatment of colonic diverticular disease. J Clin Gastroenterol. 2010;44:113-119.